Elite Pharmaceuticals Inc /Nv/ - Understand $eltp stock

$ELTP Market Cap: $635.2 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$71.17M

TTM

Gross Margin

44.76%

TTM

Net Earnings

-$6.388M

TTM

Current Assets

$45.29M

Q3 2024

Current Liabilities

$12.85M

Q3 2024

Current Ratio

352.38%

Q3 2024

Total Assets

$88.20M

Q3 2024

Total Liabilities

$40.93M

Q3 2024

Book Value

$47.27M

Q3 2024

Cash

$9.999M

Q3 2024

P/E

-99.43

Dec 02, 2024 EST

Free Cash Flow

$1.220M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	$56.63M	$34.16M	$32.26M	$25.38M	$17.99M	$7.569M	$7.459M	$7.327M	$12.50M	$5.015M	$4.601M	$3.404M
YoY Change	65.79%	5.87%	27.11%	41.05%	137.76%	1.47%	1.8%	-41.38%	149.21%	8.99%	35.19%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$56.63M	$34.16M	$32.26M	$25.38M	$17.99M	$7.569M	$7.459M	$7.327M	$12.50M	$5.015M	$4.601M	$3.404M
Cost Of Revenue	$30.27M	$17.56M	$17.47M	$13.51M	$10.02M	$4.701M	$3.511M	$5.898M	$4.484M	$3.014M	$3.236M	$2.315M
Gross Profit	$26.36M	$16.59M	$14.80M	$11.87M	$7.979M	$2.868M	$3.948M	$3.739M	$8.014M	$2.002M	$1.365M	$1.088M
Gross Profit Margin	46.55%	48.58%	45.86%	46.76%	44.34%	37.89%	52.93%	51.03%	64.12%	39.91%	29.67%	31.98%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Selling, General & Admin	$7.305M	$5.162M	$4.478M	$3.336M	$3.412M	$3.220M	$2.577M	$2.441M	$3.237M	$3.164M
YoY Change	41.53%	15.26%	34.23%	-2.22%	5.96%	24.95%	5.57%	-24.57%	2.29%
% of Gross Profit	27.72%	31.11%	30.27%	28.11%	42.76%	112.29%	65.28%	65.28%	40.39%	158.08%
Research & Development	$6.883M	$6.200M	$4.051M	$5.113M	$5.532M	$7.600M	$9.621M	$8.302M	$12.43M	$14.73M	$3.959M	$975.3K
YoY Change	11.02%	53.04%	-20.76%	-7.59%	-27.2%	-21.01%	15.9%	-33.21%	-15.61%	271.97%	305.98%
% of Gross Profit	26.12%	37.36%	27.38%	43.08%	69.34%	265.03%	243.73%	222.01%	155.09%	735.77%	290.0%	89.61%
Depreciation & Amortization	$1.321M	$1.278M	$1.209M	$1.314M	$1.320M	$1.257M	$996.4K	$714.5K	$666.5K	$581.9K	$453.7K	$423.3K	$480.0K	$480.0K	$510.0K	$500.0K	$410.0K	$440.0K	$490.0K	$360.0K	$330.0K	$310.0K	$270.0K	$200.0K	$90.00K
YoY Change	3.36%	5.67%	-7.97%	-0.45%	5.0%	26.15%	39.45%	7.21%	14.54%	28.23%	7.18%	-11.8%	0.0%	-5.88%	2.0%	21.95%	-6.82%	-10.2%	36.11%	9.09%	6.45%	14.81%	35.0%	122.22%	80.0%
% of Gross Profit	5.01%	7.7%	8.17%	11.07%	16.54%	43.83%	25.24%	19.11%	8.32%	29.07%	33.23%	38.9%
Operating Expenses	$15.57M	$12.92M	$9.725M	$9.763M	$10.26M	$12.03M	$13.00M	$11.10M	$16.33M	$18.51M	$6.649M	$2.652M
YoY Change	20.52%	32.84%	-0.39%	-4.89%	-14.65%	-7.48%	17.16%	-32.06%	-11.77%	178.37%	150.76%
Operating Profit	$10.79M	$3.676M	$5.071M	$2.105M	-$2.285M	-$9.159M	-$9.051M	-$7.356M	-$8.317M	-$16.51M	-$5.284M	-$1.563M
YoY Change	193.49%	-27.51%	140.94%	-192.09%	-75.05%	1.19%	23.05%	-11.55%	-49.62%	212.42%	238.01%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$588.6K	$1.113M	$1.234M	$978.1K	-$1.455M	-$167.7K	$4.332M	$238.2K	$280.7K	$287.2K	$859.3K	$253.7K
YoY Change	-47.1%	-9.81%	26.14%	-167.2%	768.04%	-103.87%	1718.58%	-15.12%	-2.28%	-66.57%	238.66%
% of Operating Profit	5.46%	30.27%	24.33%	46.47%
Other Income/Expense, Net	-$10.33M	$309.9K	$1.234M				$4.332M	$9.300M	$7.113M	$21.72M	-$36.27M	$2.697M
YoY Change	-3432.24%	-74.88%					-53.41%	30.73%	-67.26%	-159.9%	-1444.65%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	$463.1K	$3.986M	$6.304M	$4.145M	-$2.238M	-$9.955M	-$4.719M	$1.944M	-$1.203M	$5.217M	-$41.55M	$1.134M
YoY Change	-88.38%	-36.78%	52.12%	-285.16%	-77.52%	110.96%	-342.8%	-261.5%	-123.07%	-112.56%	-3763.65%
Income Tax	-$19.60M	$424.0K	-$1.736M		$2.000K	-$676.0K	-$1.046M	-$1.868M	-$520.5K	-$3.249K	-$292.6K
% Of Pretax Income	-4232.42%	10.64%	-27.54%					-96.09%		-0.06%
Net Earnings	$20.11M	$3.562M	$8.041M	$5.088M	-$2.240M	-$9.279M	-$3.673M	$3.811M	-$683.0K	$5.221M	-$41.26M	$1.488M
YoY Change	464.56%	-55.7%	58.02%	-327.13%	-75.86%	152.62%	-196.38%	-658.0%	-113.08%	-112.65%	-2873.04%
Net Earnings / Revenue	35.51%	10.43%	24.92%	20.05%	-12.45%	-122.6%	-49.25%	52.02%	-5.46%	104.09%	-896.71%	43.72%
Basic Earnings Per Share	$0.02	$0.00	$0.01				$0.00	$0.03	-$0.01	$0.05	-$0.21	$0.00
Diluted Earnings Per Share	$0.02	$0.00	$7.956K	$5.396K	-$2.692K	-$11.40K	-$4.614K	-$0.01	-$0.01	-$0.02	-$0.21	$0.00

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Cash & Short-Term Investments	$7.106M	$7.832M	$8.535M	$3.193M	$1.132M	$2.278M	$7.179M	$10.59M	$11.51M	$7.464M	$6.940M	$370.0K	$670.0K	$1.830M	$580.0K	$280.0K	$3.700M	$2.050M	$8.920M	$3.900M	$2.110M	$3.260M	$6.950M	$7.300M	$3.940M
YoY Change	-9.27%	-8.24%	167.33%	182.11%	-50.31%	-68.27%	-32.24%	-7.97%	54.23%	7.55%	1775.68%	-44.78%	-63.39%	215.52%	107.14%	-92.43%	80.49%	-77.02%	128.72%	84.83%	-35.28%	-53.09%	-4.79%	85.28%
Cash & Equivalents												$370.0K	$670.0K	$1.830M	$580.0K	$280.0K	$3.700M	$2.050M	$8.920M	$3.900M	$2.110M	$3.260M	$6.850M	$7.300M	$3.940M
Short-Term Investments																						$0.00	$100.0K	$0.00
Other Short-Term Assets	$524.2K	$1.033M	$527.0K	$492.6K	$870.2K	$741.4K	$949.3K	$468.0K	$377.8K	$388.1K	$320.0K	$150.0K	$130.0K	$130.0K	$130.0K	$330.0K	$180.0K	$1.150M	$1.640M	$460.0K	$340.0K	$230.0K	$320.0K	$390.0K	$910.0K
YoY Change	-49.25%	95.99%	6.97%	-43.39%	17.38%	-21.9%	102.84%	23.89%	-2.66%	21.27%	113.33%	15.38%	0.0%	0.0%	-60.61%	83.33%	-84.35%	-29.88%	256.52%	35.29%	47.83%	-28.13%	-17.95%	-57.14%
Inventory	$12.93M	$9.551M	$6.741M	$5.013M	$4.142M	$4.516M	$4.898M	$6.416M	$3.294M	$3.032M	$1.930M	$1.360M	$300.0K	$620.0K	$1.370M	$1.700M	$2.120M
Prepaid Expenses
Receivables	$19.45M	$3.095M	$3.058M	$3.496M	$4.107M	$1.322M	$675.9K	$934.1K	$1.530M	$1.446M	$730.0K	$670.0K	$400.0K	$570.0K	$400.0K	$0.00	$150.0K	$220.0K	$0.00	$140.0K	$150.0K	$10.00K	$570.0K	$90.00K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$40.01M	$21.51M	$18.86M	$12.19M	$10.25M	$8.857M	$13.70M	$18.41M	$16.71M	$12.33M	$9.920M	$2.540M	$1.500M	$3.150M	$2.490M	$2.320M	$6.150M	$3.410M	$10.56M	$4.500M	$2.600M	$3.500M	$7.840M	$7.780M	$4.850M
YoY Change	86.02%	14.04%	54.67%	18.96%	15.75%	-35.37%	-25.58%	10.16%	35.55%	24.3%	290.55%	69.33%	-52.38%	26.51%	7.33%	-62.28%	80.35%	-67.71%	134.67%	73.08%	-25.71%	-55.36%	0.77%	60.41%
Property, Plant & Equipment	$14.61M	$10.44M	$6.985M	$6.864M	$7.591M	$8.444M	$8.994M	$9.039M	$8.111M	$6.402M	$4.200M	$4.030M	$4.280M	$4.120M	$4.100M	$4.580M	$5.010M	$5.450M	$4.310M	$4.200M	$4.090M	$4.390M	$3.870M	$3.890M	$2.480M
YoY Change	39.95%	49.45%	1.76%	-9.58%	-10.1%	-6.11%	-0.51%	11.45%	26.69%	52.42%	4.22%	-5.84%	3.88%	0.49%	-10.48%	-8.58%	-8.07%	26.45%	2.62%	2.69%	-6.83%	13.44%	-0.51%	56.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$94.24K	$21.02K	$91.74K	$91.74K	$75.53K	$69.38K	$81.93K	$50.85K	$48.71K	$198.5K	$3.350M	$3.340M	$3.340M	$3.360M	$3.340M	$3.340M	$3.340M	$10.00K	$10.00K	$0.00	$400.0K	$0.00	$190.0K	$0.00	$1.320M
YoY Change	348.33%	-77.09%	0.0%	21.46%	8.86%	-15.32%	61.12%	4.39%	-75.46%	-94.08%	0.3%	0.0%	-0.6%	0.6%	0.0%	0.0%	33300.0%	0.0%		-100.0%		-100.0%		-100.0%
Other Assets	$22.59M	$2.584M	$2.577M	$405.0K	$404.8K	$398.1K	$391.6K	$389.1K	$389.0K	$607.5K	$500.0K	$510.0K	$540.0K	$570.0K	$580.0K	$660.0K	$770.0K	$780.0K	$760.0K	$470.0K	$660.0K	$700.0K	$710.0K	$480.0K	$490.0K
YoY Change	774.28%	0.29%	536.25%	0.05%	1.68%	1.68%	0.64%	0.03%	-35.98%	21.51%	-1.96%	-5.56%	-5.26%	-1.72%	-12.12%	-14.29%	-1.28%	2.63%	61.7%	-28.79%	-5.71%	-1.41%	47.92%	-2.04%
Total Long-Term Assets	$43.64M	$19.39M	$16.29M	$13.99M	$14.71M	$15.55M	$17.18M	$15.90M	$14.96M	$13.59M	$14.40M	$8.590M	$8.810M	$8.640M	$8.120M	$8.600M	$9.160M	$6.280M	$5.140M	$4.750M	$5.250M	$5.200M	$4.880M	$4.570M	$4.310M
YoY Change	125.11%	19.02%	16.38%	-4.83%	-5.4%	-9.52%	8.06%	6.27%	10.09%	-5.63%	67.64%	-2.5%	1.97%	6.4%	-5.58%	-6.11%	45.86%	22.18%	8.21%	-9.52%	0.96%	6.56%	6.78%	6.03%
Total Assets	$83.65M	$40.90M	$35.15M	$26.19M	$24.96M	$24.40M	$30.88M	$34.31M	$31.67M	$25.92M	$24.32M	$11.13M	$10.31M	$11.79M	$10.61M	$10.92M	$15.31M	$9.690M	$15.70M	$9.250M	$7.850M	$8.700M	$12.72M	$12.35M	$9.160M
YoY Change
Accounts Payable	$2.714M	$2.447M	$1.431M	$929.7K	$1.578M	$1.375M	$1.658M	$1.050M	$1.804M	$3.998M	$2.210M	$1.330M	$1.070M	$940.0K	$990.0K	$980.0K	$850.0K	$2.210M	$1.740M	$880.0K	$1.090M	$0.00	$440.0K	$70.00K	$600.0K
YoY Change	10.93%	70.99%	53.92%	-41.08%	14.72%	-17.05%	57.95%	-41.82%	-54.86%	80.88%	66.17%	24.3%	13.83%	-5.05%	1.02%	15.29%	-61.54%	27.01%	97.73%	-19.27%		-100.0%	528.57%	-88.33%
Accrued Expenses	$5.713M	$5.063M	$4.896M	$4.459M	$5.029M	$3.714M	$1.789M	$794.6K	$555.4K
YoY Change	12.85%	3.4%	9.81%	-11.35%	35.43%	107.63%	125.08%	43.09%
Deferred Revenue
YoY Change
Short-Term Debt	$4.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$718.3K	$583.1K	$530.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change								-100.0%	23.19%	10.01%
Long-Term Debt Due	$609.0K	$310.9K	$353.8K	$410.8K	$1.852M	$653.9K	$654.7K	$487.0K	$548.8K	$475.2K	$3.400M	$3.990M	$3.400M	$3.400M	$3.470M	$220.0K	$210.0K	$190.0K	$180.0K	$290.0K	$230.0K	$220.0K	$210.0K	$120.0K	$120.0K
YoY Change	95.9%	-12.15%	-13.87%	-77.82%	183.3%	-0.12%	34.44%	-11.26%	15.49%	-86.02%	-14.79%	17.35%	0.0%	-2.02%	1477.27%	4.76%	10.53%	5.56%	-37.93%	26.09%	4.55%	4.76%	75.0%	0.0%
Total Short-Term Liabilities	$13.05M	$7.834M	$6.694M	$5.813M	$8.640M	$6.906M	$5.115M	$3.345M	$4.640M	$5.069M	$6.160M	$5.360M	$4.550M	$4.670M	$4.760M	$1.560M	$1.120M	$2.390M	$1.950M	$1.180M	$1.310M	$550.0K	$780.0K	$410.0K	$710.0K
YoY Change	66.59%	17.02%	15.17%	-32.72%	25.1%	35.03%	52.92%	-27.92%	-8.46%	-17.71%	14.93%	17.8%	-2.57%	-1.89%	205.13%	39.29%	-53.14%	22.56%	65.25%	-9.92%	138.18%	-29.49%	90.24%	-42.25%
Long-Term Debt	$4.760M	$3.562M	$1.389M	$1.741M	$1.800M	$3.327M	$3.331M	$2.162M	$2.176M	$2.065M	$0.00	$0.00	$10.00K	$10.00K	$20.00K	$3.420M	$3.640M	$3.800M	$3.980M	$2.370M	$2.500M	$2.720M	$2.940M	$2.770M	$2.890M
YoY Change	33.65%	156.43%	-20.21%	-3.31%	-45.88%	-0.14%	54.11%	-0.65%	5.36%			-100.0%	0.0%	-50.0%	-99.42%	-6.04%	-4.21%	-4.52%	67.93%	-5.2%	-8.09%	-7.48%	6.14%	-4.15%
Other Long-Term Liabilities	$8.261M	$540.6K	$1.844M	$2.484M	$3.861M	$2.773M	$3.961M	$3.141M	$13.69M	$18.52M	$99.36M	$14.44M	$20.74M	$24.98M	$16.42M	$0.00						$0.00	$850.0K	$0.00
YoY Change	1428.11%	-70.68%	-25.78%	-35.65%	39.22%	-29.99%	26.12%	-77.07%	-26.04%	-81.36%	588.09%	-30.38%	-16.97%	52.13%								-100.0%
Total Long-Term Liabilities	$13.02M	$4.102M	$3.233M	$4.225M	$5.661M	$6.100M	$7.292M	$5.302M	$15.87M	$20.58M	$99.36M	$14.44M	$20.75M	$24.99M	$16.44M	$3.420M	$3.640M	$3.800M	$3.980M	$2.370M	$2.500M	$2.720M	$3.790M	$2.770M	$2.890M
YoY Change	217.42%	26.9%	-23.49%	-25.37%	-7.19%	-16.36%	37.53%	-66.59%	-22.89%	-79.29%	588.09%	-30.41%	-16.97%	52.01%	380.7%	-6.04%	-4.21%	-4.52%	67.93%	-5.2%	-8.09%	-28.23%	36.82%	-4.15%
Total Liabilities	$26.07M	$11.94M	$9.927M	$10.04M	$14.30M	$13.01M	$12.41M	$8.647M	$20.51M	$25.65M	$105.5M	$19.80M	$25.30M	$29.66M	$21.20M	$4.980M	$4.760M	$6.190M	$5.930M	$3.540M	$3.810M	$3.270M	$4.570M	$3.170M	$3.600M
YoY Change	118.43%	20.24%	-1.1%	-29.81%	9.96%	4.83%	43.48%	-57.84%	-20.04%	-75.69%	432.93%	-21.74%	-14.7%	39.91%	325.7%	4.62%	-23.1%	4.38%	67.51%	-7.09%	16.51%	-28.45%	44.16%	-11.94%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding	1.015B shares	1.013B shares	1.011B shares	796.1M shares	838.7M shares	673.9M shares	591.2M shares	463.0M shares	349.1M shares
Diluted Shares Outstanding	1.023B shares	1.013B shares	1.011B shares	798.2M shares	844.5M shares	673.9M shares	757.6M shares	463.0M shares	526.9M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $635.2 Million

About ELITE PHARMACEUTICALS INC /NV/

Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 64 full-time employees. The company went IPO on 2014-02-20. The firm specializes in developing and manufacturing oral, controlled-release drug products. The company owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.

Industry: Pharmaceutical Preparations Peers: TALPHERA, INC. ALIMERA SCIENCES INC Hepion Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. JOHNSON & JOHNSON NVN Liquidation, Inc. NutriBand Inc. REVIVA PHARMACEUTICALS HOLDINGS, INC. Zynerba Pharmaceuticals, Inc.